TFF PHARMACEUTICALS, INC. Comprehensive Income
TFF PHARMACEUTICALS, INC. reported Comprehensive Income of -$3.53 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-20.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2024-11-20
- TFF PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-09-30 was -$3.53M.
- TFF PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-06-30 was -$4.46M.
- TFF PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-03-31 was -$5.79M.
- TFF PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-12-31 was -$4.71M.
- TFF PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$21.25M.
- TFF PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$31.86M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$3.53M 10-Q · filed 2024-11-20 | -$7.99M derived: sum of 2 quarters · filed 2024-11-20 | -$13.78M 10-Q · filed 2024-11-20 | -$18.48M derived: sum of 4 quarters · filed 2024-11-20 |
| 2024-06-30 | -$4.46M 10-Q · filed 2024-08-14 | -$10.25M 10-Q · filed 2024-08-14 | -$14.96M derived: sum of 3 quarters · filed 2024-08-14 | -$19.41M derived: sum of 4 quarters · filed 2024-11-20 |
| 2024-03-31 | -$5.79M 10-Q · filed 2024-05-14 | -$10.50M derived: sum of 2 quarters · filed 2024-05-14 | -$14.95M derived: sum of 3 quarters · filed 2024-11-20 | -$19.97M derived: sum of 4 quarters · filed 2024-11-20 |
| 2023-12-31 | -$4.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$9.15M derived: sum of 2 quarters · filed 2024-11-20 | -$14.18M derived: sum of 3 quarters · filed 2024-11-20 | -$21.25M 10-K · filed 2024-03-28 |
| 2023-09-30 | -$4.45M 10-Q · filed 2024-11-20 | -$9.48M derived: sum of 2 quarters · filed 2024-11-20 | -$16.55M 10-Q · filed 2024-11-20 | -$23.85M derived: sum of 4 quarters · filed 2024-11-20 |
| 2023-06-30 | -$5.03M 10-Q · filed 2024-08-14 | -$12.10M 10-Q · filed 2024-08-14 | -$19.40M derived: sum of 3 quarters · filed 2024-08-14 | -$26.78M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$7.07M 10-Q · filed 2024-05-14 | -$14.37M derived: sum of 2 quarters · filed 2024-05-14 | -$21.75M derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$7.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$14.68M derived: sum of 2 quarters · filed 2024-03-28 | -$31.86M 10-K · filed 2024-03-28 | |
| 2022-09-30 | -$7.38M 10-Q · filed 2023-11-14 | -$24.56M 10-Q · filed 2023-11-14 |